Literature DB >> 2076474

Characterization of 5-HT3 and 'atypical' 5-HT receptors mediating guinea-pig ileal contractions in vitro.

R M Eglen1, S R Swank, L K Walsh, R L Whiting.   

Abstract

1. Neuronal 5-hydroxytryptamine (5-HT) receptors mediating contraction of guinea-pig ileal segments have been characterized in vitro by the use of methysergide to block 5-HT1-like and 5-HT2 receptors. Concentration-response curves to 5-HT were biphasic (first phase, defined as those responses occurring between 1 nM and 0.32 microM 5-HT, -log EC50 = 7.15 +/- 0.08; second phase, defined as these responses occurring between 0.32 microM and 32 microM 5-HT, -log EC50 = 5.32 +/- 0.03) but monophasic to 5-methoxytryptamine (-log EC50 = 7.0 +/- 0.08) and 2 methyl 5-HT (-log EC50 = 5.2 +/- 0.13). The maximal response of the first phase to 5-HT and the maximal response to 5-methoxytryptamine were 30 +/- 4% and 35 +/- 5% respectively of the maximum response to the second phase of the 5-HT concentration-effect curve (set at 100%). In contrast, the maximal response to 2-methyl-5-HT equalled that obtained with 5-HT (second phase). 2. The responses comprising the second phase of the concentration-effect curve to 5-HT were antagonized by 1 microM ICS 205-930, ondansetron, granisetron, quipazine, N-methyl-quipazine and (R,S)-zacopride and the following pKB values, with 5-HT as the agonist, were obtained at the 5-HT3 receptor: ICS 205-930 7.61 +/- 0.05, ondansetron 6.90 +/- 0.04, granisetron 7.90 +/- 0.04, (S)-zacopride 8.11 +/- 0.06, (R,S)-zacopride 7.64 +/- 0.11, and (R)-zacopride 7.27 +/- 0.06. 3. Under conditions of 5-HT1-like, 5-HT2 and 5-HT3 receptor blockade, the following rank order of agonism was observed: 5-HT > 5-methoxytryptamine = renzapride > (S)-zacopride > (R,S-zacopride > 5-carboxamidotryptamine > BRL 24682 > (R-zacopride > metoclopramide > 2-methyl-5-HT > sulpiride. 8-Dihydroxydiphenylaminotetralin (8-OHDPAT), GR 43175, N,N-dipropyl-5-carboxamidotryptamine, ondansetron, ICS 205-930, granisetron, quipazine and N-methyl-quipazine were inactive as agonists and antagonists. Relative to 5-HT, (R,S)-zacopride acted as a partial agonist (intrinsic activity, alpha = 0.80; -log EC50 = 6.3 + 0.12; -log KA = 6.1 + 0.03) as did (R)-zacopride (alpha = 0.4, -log EC,0 5.7 + 0.08, -log KA = 5.5 + 0.11). (S)-zacopride acted as a full agonist (-log EC,0 = 6.9 + 0.03). ICS 205-930 (3 microM) antagonized competitively responses to 5-HT, 5 methoxytryptamine, (RS)- and (S)- zacopride and 5-carboxamidotryptamine yielding -log KB estimates ranging from 6.1-6.5. 4. It is concluded that two different 5-HT receptors mediate excitatory neuronal responses in the guineapig ileum. 5-HT3 receptors mediate the second phase of the biphasic concentration-response curve, whereas a receptor with properties distinct from the 5-HT1-like, 5-HT2 and 5-HT3 subtypes mediates the initial phase of the concentration-response curve. This receptor, which exhibits a close similarity to the 5-HT4 subtype is: (1) stimulated by 5-methoxytryptamine but not 2-methyl-5-HT; (2) stimulated selectively by certain substituted benzamides; (3) recognizes the optical isomers of zacopride and (4) is blocked by relatively high concentrations ICS 205-930 (pKB = 6.0-6.5) but not ondansetron, granisetron, quipazine or N-methyl-quipazine.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2076474      PMCID: PMC1917750          DOI: 10.1111/j.1476-5381.1990.tb14113.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  28 in total

1.  BRL 24924: a potent agonist at a non-classical 5-HT receptor positively coupled with adenylate cyclase in colliculi neurons.

Authors:  A Dumuis; M Sebben; J Bockaert
Journal:  Eur J Pharmacol       Date:  1989-03-21       Impact factor: 4.432

Review 2.  The classification of 5-hydroxytryptamine receptors.

Authors:  E J Mylecharane
Journal:  Clin Exp Pharmacol Physiol       Date:  1989-06       Impact factor: 2.557

3.  Comparison of the positive chronotropic response to 5-hydroxytryptamine with beta-adrenoceptor agonists on the guinea pig atria in vitro.

Authors:  R M Eglen; R L Whiting
Journal:  J Cardiovasc Pharmacol       Date:  1989-01       Impact factor: 3.105

4.  Pharmacological estimation of drug-receptor dissociation constants. Statistical evaluation. I. Agonists.

Authors:  R B Parker; D R Waud
Journal:  J Pharmacol Exp Ther       Date:  1971-04       Impact factor: 4.030

5.  The sites of action of 5-hydroxytryptamine in nerve-muscle preparations from the guinea-pig small intestine and colon.

Authors:  M Costa; J B Furness
Journal:  Br J Pharmacol       Date:  1979-02       Impact factor: 8.739

6.  A nonclassical 5-hydroxytryptamine receptor positively coupled with adenylate cyclase in the central nervous system.

Authors:  A Dumuis; R Bouhelal; M Sebben; R Cory; J Bockaert
Journal:  Mol Pharmacol       Date:  1988-12       Impact factor: 4.436

7.  Inhibition by morphine of the release of acetylcholine from the intestine of the guinea-pig.

Authors:  W SCHAUMANN
Journal:  Br J Pharmacol Chemother       Date:  1957-03

8.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

9.  Two types of receptors for 5-hydroxytryptamine on the cholinergic nerves of the guinea-pig myenteric plexus.

Authors:  H Kilbinger; I Pfeuffer-Friederich
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

10.  Antagonism of some contractile responses to prostaglandins by cyproheptadine.

Authors:  V M Ganatra; V R Dhumal; J D Bhatt; K S Sachdev
Journal:  Arch Int Pharmacodyn Ther       Date:  1979-08
View more
  32 in total

Review 1.  Neuropharmacology of emesis in relation to clinical response.

Authors:  B Costall; R J Naylor
Journal:  Br J Cancer Suppl       Date:  1992-12

2.  A comparative study of functional 5-HT4 receptors in human colon, rat oesophagus and rat ileum.

Authors:  P G McLean; I M Coupar; P Molenaar
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

3.  Characterization of the 5-HT4 receptor mediating tachycardia in piglet isolated right atrium.

Authors:  A D Medhurst; A J Kaumann
Journal:  Br J Pharmacol       Date:  1993-11       Impact factor: 8.739

4.  Differences in response to 5-HT4 receptor agonists and antagonists of the 5-HT4-like receptor in human colon circular smooth muscle.

Authors:  F S Tam; K Hillier; K T Bunce; C Grossman
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

5.  Ability of 5-HT4 receptor ligands to modulate rat striatal dopamine release in vitro and in vivo.

Authors:  L J Steward; J Ge; R L Stowe; D C Brown; R K Bruton; P R Stokes; N M Barnes
Journal:  Br J Pharmacol       Date:  1996-01       Impact factor: 8.739

6.  New insights into the human 5-HT4 receptor binding site: exploration of a hydrophobic pocket.

Authors:  Lucie Rivail; Mireille Giner; Monique Gastineau; Magali Berthouze; Jean-Louis Soulier; Rodolphe Fischmeister; Frank Lezoualc'h; Bernard Maigret; Sames Sicsic; Isabelle Berque-Bestel
Journal:  Br J Pharmacol       Date:  2004-09-06       Impact factor: 8.739

7.  Differential modulation of extracellular levels of 5-hydroxytryptamine in the rat frontal cortex by (R)- and (S)-zacopride.

Authors:  N M Barnes; C H Cheng; B Costall; J Ge; R J Naylor
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

8.  Comparison of 5-HT4 receptors in guinea-pig colon and rat oesophagus: effects of novel agonists and antagonists.

Authors:  E Leung; M T Pulido-Rios; D W Bonhaus; L A Pekins; K D Zeitung; S A Hsu; R D Clark; E H Wong; R M Eglen
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-07       Impact factor: 3.000

9.  5-Hydroxytryptamine4 receptors mediate relaxation of the rat oesophageal tunica muscularis mucosae.

Authors:  G S Baxter; D A Craig; D E Clarke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

10.  Development of a radioligand binding assay for 5-HT4 receptors in guinea-pig and rat brain.

Authors:  C J Grossman; G J Kilpatrick; K T Bunce
Journal:  Br J Pharmacol       Date:  1993-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.